Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
294,683,714
-
Number of holders
-
189
-
Total 13F shares, excl. options
-
76,183,727
-
Shares change
-
-3,214,601
-
Total reported value, excl. options
-
$911,820,230
-
Value change
-
-$39,619,833
-
Put/Call ratio
-
79%
-
Number of buys
-
71
-
Number of sells
-
-92
-
Price
-
$11.97
Significant Holders of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) as of Q2 2021
230 filings reported holding SGMO - SANGAMO THERAPEUTICS, INC - Common Stock as of Q2 2021.
SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) has 189 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 76,183,727 shares
of 294,683,714 outstanding shares and own 26% of the company stock.
Largest 10 shareholders include WASATCH ADVISORS INC (10,304,295 shares), BlackRock Inc. (9,783,968 shares), VANGUARD GROUP INC (9,105,258 shares), STATE STREET CORP (5,994,166 shares), CREDIT SUISSE AG/ (3,597,551 shares), JPMORGAN CHASE & CO (3,276,787 shares), DIMENSIONAL FUND ADVISORS LP (3,006,478 shares), GEODE CAPITAL MANAGEMENT, LLC (2,060,536 shares), GOLDMAN SACHS GROUP INC (1,553,541 shares), and NORTHERN TRUST CORP (1,491,442 shares).
This table shows the top 189 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.